Patent ID: 9045535
Filing Date: 2015-06-02
Classification: A61K,A61P,C07K

Abstract:
1. A process for the production of a huTNFR1-antagonist comprising the steps of a) providing a proteinaceous construct comprising a humanized antibody or at least one fragment thereof having i) one or more amino acid sequences of human origin capable of reducing the immunogenic response of said huTNFR1-antagonist in humans, and ii) one or more amino acid sequences of non-human origin capable of selectively binding to huTNFR1 thereby completely blocking the TNFR1 activity, wherein the proteinaceous construct comprises the amino acid sequence according to SEQ NO.: 7 as variable domain of the heavy chain (VH) and the amino acid sequence according to SEQ NO.: 8 as variable domain of the light chain (VL), or a fragment of a humanized antibody, wherein the fragment is a scFv comprising the amino acid sequence according to SEQ ID NO.: 9; b) identifying one or more amino acid sequences capable of binding selectively to huTNFR1 by guided selection using one or more of the amino acid sequences of the proteinaceous construct, and c) constructing the antagonist comprising at least one or more of the amino acid sequences identified under step (b).